ACQUISITIONS and MERGERS

MedAlliance has been acquired by Cordis for a 2022 investment of $35M and a 2023 upfront closing payment of $200M, together with regulatory achievement milestones of up to $125M and commercial milestones of up to $775M through 2029, for a total consideration of up to $1.135 Billion. 

"Through our AOS offerings, we've been leading the way in melding innovative technology with clinical expertise to help address these challenges," commented Chuck Lindley, Vice President of AOS, at Varian. "With Aspekt Solutions, we can support more oncology centers with a holistic approach to addressing today's challenges while also preparing for the fast-evolving future of cancer care."

“These transactions represent a transformative event for the Company,” commented Soren Christiansen, Board Chairman of Sharps Technology. “Recruiting Robert Hayes as our CEO two years ago was a substantial achievement for Sharps Technology and its shareholders. Robert has built a strong team, and together they worked through a successful, multi-month financing process that resulted in selecting a funding partner that is poised to provide up to $75 Million in debt financing to be used for the transaction.

″We anticipate this novel, clinically-backed technology can support our category leadership strategy while expanding access to care for individuals who need personalized treatment,″ said Jim Cassidy, president, Neuromodulation, Boston Scientific. ″Upon close, we look forward to working with the Relievant team to explore opportunities to bring this high-growth therapy to a wider population of people living with chronic low back pain.″

Randy Theken, Founder of Theken Companies, said of the acquisition, "I was truly overwhelmed by the technology created by the VisionAir team at Cleveland Clinic. The VisionAir 3D Patient-Specific Stents provide significantly improved stent life and an improved patient quality of life. This is exciting not only for the pulmonary field, but for the potential to apply this technology to other medical devices."

Abdul Mutlib, CEO of Frontage Laboratories.  "Nucro-Technics has been recognized as a leader in the Canadian CRO market for over 50 years, and its unparalleled client services are a perfect match for the culture of Frontage Laboratories.  This acquisition not only significantly strengthens our presence in Canada, but also will enable the combined organization to offer a more expansive suite of services to clients across the globe.  We are looking forward to partnering with the Nucro team to deliver the world-class expertise that clients have come to expect from us."

Thomas Scientific's CEO, Stan Haas, stated, "We at Thomas Scientific are very proud to partner with an industry veteran in Billy Day and his entire team. Billy has built a business over the past 45 years founded on providing personalized service and many great product brands to meet the stringent needs of their customers. By Day Associates joining the Thomas Scientific family of companies, the customers will have access to an even broader portfolio of products and a national network of distribution centers and inventory to meet their needs now and into the future."

"MD Revolution offers not only extensive experience but also the best technology platform, and proven SaaS offering, to serve our growing client base" said Rick Griffin, CEO, NavCare. "We share the same culture and desire to provide exceptional personalized care to our patients, along with maintaining the highest clinical standards."